Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million on August 18, 2023. In similar transaction Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million. Qingdao Laoshan District Finance Bureau and Qingdao State-owned Assets Supervision and Administration Commission, approved for Huilong Huaze to acquire 9,720,000 shares in Hangzhou TianMuShan from Yongxin Huarui.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.78 CNY | -0.11% | -1.24% | -24.70% |
1st Jan change | Capi. | |
---|---|---|
-24.70% | 148M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- 600671 Stock
- News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
- Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.